Short answer: Topical finasteride is a 5-alpha-reductase inhibitor formulated for direct application to the scalp, used in androgenetic alopecia with the aim of reducing local dihydrotestosterone (DHT) while limiting the systemic exposure associated with oral finasteride. Randomised controlled trials — including a phase III trial of a topical finasteride spray and several combination studies pairing topical finasteride with minoxidil — report improvements in hair density and target-area hair count, with the combination generally outperforming minoxidil alone. A systematic review and a network meta-analysis place topical finasteride among the effective options for male pattern hair loss. In Malaysia, a compounded topical finasteride preparation — as a topical liquid, serum or cream — is prepared only on a registered doctor’s prescription, under Good Compounding Practice (GCP), for one named patient. This guide summarises the evidence a prescriber needs before referring.
Why topical finasteride exists as a prescribing option
Androgenetic alopecia is driven by the progressive miniaturisation of genetically susceptible scalp follicles under the influence of DHT, a potent androgen converted from testosterone by the enzyme 5-alpha-reductase. Oral finasteride at 1 mg daily inhibits this enzyme systemically and has a well-established evidence base, but it also produces measurable systemic exposure — the reason some patients and prescribers seek a route that concentrates the effect at the scalp.
Topical finasteride addresses that question by delivering the active directly to the skin where follicular DHT is produced. A systematic review of topical finasteride in androgenetic alopecia, covering both male and female patients, concluded that topical formulations show efficacy in improving hair growth parameters, with a lower incidence of sexual side effects than oral finasteride in the studies reviewed (Lee et al., 2018, Journal of Drugs in Dermatology, PMID 29601622). The review’s authors noted that the evidence base, while encouraging, is heterogeneous in formulation and study design — a limitation prescribers should weigh.
A more recent systematic review of androgenic alopecia management broadly confirms that topical finasteride holds a place among the pharmacological options, alongside oral finasteride, minoxidil and combination approaches (Rosenthal et al., 2024, Journal of Cosmetic and Laser Therapy, PMID 38852607).
What the clinical evidence shows
The phase III randomised trial
The most rigorous single study of topical finasteride to date is a phase III, randomised, controlled clinical trial of a topical finasteride spray solution in male androgenetic alopecia (Piraccini et al., 2022, Journal of the European Academy of Dermatology and Venereology, PMID 34634163). The trial reported a statistically significant improvement in target-area hair count versus vehicle control, with adverse-event rates broadly comparable to the vehicle group. This study provides the strongest individual-trial evidence for topical finasteride as a standalone preparation.
Combination therapy: topical finasteride with minoxidil
Several randomised trials have examined the combination of topical finasteride with topical minoxidil, which is the most common compounded configuration a prescriber requests. The rationale is mechanistic: minoxidil is thought to prolong the anagen (growth) phase and increase follicle size, while finasteride reduces the DHT that drives miniaturisation — two different targets in one vehicle.
A randomised controlled trial of topical 0.1% finasteride combined with 5% minoxidil versus 5% minoxidil alone in male androgenetic alopecia reported significantly greater improvements in hair density and hair diameter with the combination (Lubis et al., 2025, Archives of Dermatological Research, PMID 40208341).
An earlier randomised, double-blind study compared 3% minoxidil combined with 0.1% finasteride against 3% minoxidil alone, and the combination group showed superior outcomes in hair count and patient-reported improvement (Tanglertsampan, 2012, Journal of the Medical Association of Thailand, PMID 23193746).
A randomised, double-blind controlled study of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil alone similarly favoured the combination for hair count improvement (Suchonwanit et al., 2018, Journal of the European Academy of Dermatology and Venereology, PMID 29972712).
A more recent randomised trial comparing 0.25% topical finasteride with 5% minoxidil against 5% minoxidil alone reported significantly greater improvement in the combination arm (Asad et al., 2024, Journal of Drugs in Dermatology, PMID 39496123).
A prospective, randomised, controlled, assessor-blinded, three-arm pilot trial compared the combination of topical minoxidil and topical finasteride against each used in monotherapy. The combination group showed greater improvement in hair density measures than either monotherapy arm (Rossi et al., 2024, Journal of Cosmetic Dermatology, PMID 37798906).
Where topical finasteride sits in the hierarchy
A network meta-analysis comparing the relative efficacy of minoxidil and 5-alpha-reductase inhibitors in male androgenetic alopecia treatment found that both oral and topical finasteride, as well as combination therapy, ranked among the more effective interventions, though the authors noted that direct head-to-head comparisons between topical and oral finasteride remain limited (Gupta et al., 2022, JAMA Dermatology, PMID 35107565). An updated network meta-analysis published in 2025 reached broadly similar conclusions, reinforcing the position of combination topical therapy among the effective options (Gupta et al., 2025, Journal of Cosmetic Dermatology, PMID 40586152).
Systemic exposure and the pharmacokinetic question
The central question a prescriber asks about topical finasteride is whether it genuinely reduces systemic exposure compared with the oral route. A phase I, randomised, double-blind, placebo-controlled study examined the safety, tolerability and pharmacokinetics of a topical finasteride formulation (CG2001) in adult male subjects with androgenetic alopecia, providing human pharmacokinetic data on systemic absorption from a topical application (Li et al., 2026, Journal of Dermatological Treatment, PMID 41622844). The phase III spray trial (Piraccini et al., 2022) also reported adverse-event data, with sexual-side-effect rates in the topical finasteride arm comparable to vehicle — though prescribers should note that topical finasteride is still absorbed systemically to some degree, and the risk cannot be assumed to be zero.
This is an important caveat: topical finasteride is not a way to eliminate systemic risk. It is a route that aims to reduce it. The decision to use topical rather than oral finasteride belongs to the prescriber, informed by the patient’s history, risk tolerance and the available evidence.
Practical prescribing considerations
Strength
The studied topical finasteride concentrations range from 0.1% to 0.25%, typically combined with minoxidil at 3% or 5%. A compounded preparation allows the prescriber to select a specific finasteride concentration and minoxidil strength within this range, prepared as a topical liquid at the exact concentration the doctor selects. This is relevant when a prescriber wishes to start below the studied concentration and titrate, or when a patient has previously tolerated a particular strength and the prescriber wants to maintain it.
Vehicle
The vehicle in which topical finasteride and minoxidil are delivered affects both absorption and tolerability. The clinical trials cited above used hydroalcoholic solutions and spray vehicles. A compounding pharmacy prepares the formulation in the vehicle the prescriber specifies — within the non-sterile dosage forms it prepares: topical liquid, serum or cream. The choice of vehicle is a clinical decision based on the treatment site, the patient’s skin characteristics and the climate; in Malaysia’s humidity, a vehicle that performs well in a temperate-climate trial may not be the optimal choice for every patient.
Patient selection and monitoring
Topical finasteride is not appropriate for every patient with androgenetic alopecia. The evidence base is strongest for adult males with male-pattern hair loss. Data for female pattern hair loss are more limited, and finasteride is contraindicated in pregnancy because of the risk of external genital abnormalities in a male fetus. Prescribers should document the clinical rationale, confirm the patient is not pregnant (where relevant), and plan a review at 3–6 months to assess response, as the trials report measurable outcomes over this timeframe.
Baseline photography and standardised hair-density assessment at the review visit help the prescriber judge whether the preparation is producing the intended effect. If no improvement is seen by 6–9 months, the treatment plan should be reassessed rather than simply continued.
Discussing a topical finasteride preparation with Lynnity
Lynnity Pharma is a non-sterile compounding pharmacy in Kuala Lumpur serving the Klang Valley, with enquiries also from Singapore. Every preparation — including a compounded topical finasteride with minoxidil — is made only on a registered doctor’s prescription, for one named patient, under Good Compounding Practice (GCP). The dosage forms Lynnity prepares are capsules, liquids, creams, tonics and serums; a topical finasteride preparation would be compounded as a topical liquid or serum, at the strengths the prescriber specifies.
A prescriber referring a patient sends a named-patient prescription naming the actives (finasteride and minoxidil), the requested strengths, and the dosage form, along with a brief formulation note covering the clinical rationale and any excipient considerations. The pharmacy may advise on compatibility and stability before finalising. Prescribers reading this article who also manage patients requiring compounded dermatological preparations or customised supplement formulations may find those services relevant to the same clinical workflow. A structured prescriber’s checklist for compounding referrals is available to guide the referral. To start the conversation, a clinician contacts the Lynnity team with the prescription and formulation brief; the pharmacy confirms feasibility and prepares to specification.
Medically reviewed by Vitthia Rama Murti, RPh (RPh 15632) — Last reviewed 26 September 2026.
Frequently asked questions
Is topical finasteride available in Malaysia?
There is no mass-produced, MAL-registered topical finasteride product widely available on Malaysian pharmacy shelves. A topical finasteride preparation can be compounded by a GCP-compliant pharmacy on a registered doctor’s prescription, for one named patient. This is the route clinics in Kuala Lumpur and the Klang Valley use when a prescriber decides a topical finasteride formulation is appropriate for a patient with androgenetic alopecia.
Does topical finasteride reduce systemic side effects compared with oral finasteride?
Studies suggest that topical finasteride produces lower systemic exposure than the oral route, and the phase III spray trial reported sexual-side-effect rates comparable to vehicle. However, topical finasteride is still absorbed systemically to some degree, and the risk cannot be assumed to be zero. The decision between topical and oral finasteride belongs to the prescriber, based on the patient’s individual risk profile and the available evidence.
What strength of topical finasteride is used with minoxidil?
The randomised trials studied topical finasteride concentrations of 0.1% and 0.25%, typically combined with minoxidil at 3% or 5%. A compounded preparation allows the prescriber to select a specific concentration within this range. The choice of strength is a clinical decision based on the patient’s history, prior treatment response and tolerability.
How long does it take to see results from topical finasteride?
The clinical trials report measurable outcomes over 3–6 months, with continued improvement up to 12 months. Initial shedding in the first 6–8 weeks is common and is not a sign of treatment failure. Prescribers should plan a review at 3–6 months to assess response, using standardised photography or hair-density assessment where possible.
Can topical finasteride be prescribed for female pattern hair loss?
Evidence for topical finasteride in female pattern hair loss is more limited than in male androgenetic alopecia. Finasteride is contraindicated in pregnancy due to the risk of external genital abnormalities in a male fetus. A prescriber considering topical finasteride for a female patient should weigh the limited evidence, confirm the patient is not pregnant, and document the clinical rationale carefully.